

## **Dr Linda Friedland appointed as NED of NeuroScientific**

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**”) is pleased to announce the appointment of Dr Linda Friedland as an independent Non-executive Director effective today.

Dr. Friedland is a physician with over 25 years of experience in clinical medicine and an international advisor to many Fortune and Forbes global companies. She consults with healthcare, biotech, corporate, and financial institutions. A graduate of the Australian Institute of Company Directors (GAICD), Linda is a non-executive director on several Healthcare boards within Australia and abroad. Among her roles, Dr. Friedland is Deputy Chairman of the Neurological Council of Western Australia (NCWA), senior consultant to TargImmune Therapeutics (Basel, Switzerland), co-founder and director of FFD Capital LLC (USA) and Asia- Pacific partner for Camelot BioCapital. An author of seven healthcare-related bestsellers with a long career in television and health media, she has developed public health and disease management programs in Asia, USA, Australia, Africa, and the UK and delivered keynote addresses in more than 30 countries.

NSB’s Chair Mr Paul Rennie commented: *“On behalf of the Board, I am very excited to welcome Linda to the company given her breadth of experience in healthcare sector. I, and my fellow directors, look forward to her contribution to the continued growth and success of the Company.”*

### **Grant of Options**

As part of her appointment Dr Linda Friedland will receive 2 million Performance Rights, with the following vesting milestones:

- 1 million rights to vest at 12 months of service.
- 1 million rights to vest at 24 months of service.

In accordance with the Company’s Constitution, Dr Linda Friedland will stand for election at the Company’s Annual General Meeting in November 2023.

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS

For more information please contact:

Paul Rennie  
Non-executive Chair  
ir@neuroscientific.com  
+ 61 8 6382 1805

Abby Macnish Niven  
CFO and Company Secretary  
ir@neuroscientific.com  
+ 61 8 6382 1805

**About NeuroScientific Biopharmaceuticals Ltd**

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

**About EmtinB™**

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.